{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:12:48Z","timestamp":1792498368799,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1157287"],"award-info":[{"award-number":["APP1157287"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000973","name":"Cystic Fibrosis in Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.biopha.2024.116155","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T12:01:23Z","timestamp":1705406483000},"page":"116155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Fetal drug exposure after maternally administered CFTR modulators Elexacaftor\/Tezacaftor\/Ivacaftor in a rat model"],"prefix":"10.1016","volume":"171","author":[{"given":"Danni","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Donnelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Habgood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena K.","family":"Schneider-Futschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116155_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4187\/respcare.06697","article-title":"Cystic fibrosis lung disease: an overview","volume":"65","author":"Turcios","year":"2020","journal-title":"Respir. Care"},{"key":"10.1016\/j.biopha.2024.116155_bib2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF00201659","article-title":"Heterogeneity in the severity of cystic fibrosis and the role of CFTR gene mutations","volume":"93","author":"Dean","year":"1994","journal-title":"Hum. Genet."},{"key":"10.1016\/j.biopha.2024.116155_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jmr.2447","article-title":"Drug-drug plasma protein binding interactions of ivacaftor","volume":"28","author":"Schneider","year":"2015","journal-title":"J. Mol. Recognit."},{"key":"10.1016\/j.biopha.2024.116155_bib4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1590\/S1806-37132013000300007","article-title":"Screening for F508del as a first step in the molecular diagnosis of cystic fibrosis","volume":"39","author":"Marson","year":"2013","journal-title":"J. Bras. Pneumol."},{"key":"10.1016\/j.biopha.2024.116155_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fphar.2016.00275","article-title":"CFTR modulators: shedding light on precision medicine for cystic fibrosis","volume":"7","author":"Lopes-Pacheco","year":"2016","journal-title":"Front Pharm."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.116155_bib6","doi-asserted-by":"crossref","first-page":"eS8","DOI":"10.1016\/S0929-693X(20)30044-0","article-title":"CFTR gene variants, epidemiology and molecular pathology","volume":"27","author":"Bareil","year":"2020","journal-title":"Arch. Pedia"},{"key":"10.1016\/j.biopha.2024.116155_bib7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.biopha.2024.116155_bib8","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009761","article-title":"Cystic fibrosis transmembrane regulator correctors and potentiators","volume":"3","author":"Rowe","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.biopha.2024.116155_bib9","unstructured":"US Food and Drug Administration. Trikafta (elexacaftor, tezacaftor and ivacaftor, and ivacaftor tablets), co-packeted for oral use. (2019)."},{"key":"10.1016\/j.biopha.2024.116155_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrd3723","article-title":"Ivacaftor","volume":"11","author":"Davis","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2024.116155_bib11","unstructured":"European Medicines Agency. Assessment report \u2014 Kalydeco (ivacaftor). (2012)."},{"key":"10.1016\/j.biopha.2024.116155_bib12","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.116155_bib13","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1164\/rccm.202106-1426OC","article-title":"Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis","volume":"205","author":"Gabillard-Lefort","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.biopha.2024.116155_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/apt.13486","article-title":"Exposure to acid-suppressing drugs during pregnancy and the risk of asthma in childhood: an observational cohort study","volume":"43","author":"Cea Soriano","year":"2016","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.biopha.2024.116155_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","author":"Taylor-Cousar","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.biopha.2024.116155_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jogn.2016.08.011","article-title":"A case report of pregnancy during use of targeted therapeutics for cystic fibrosis","volume":"46","author":"Ladores","year":"2017","journal-title":"J. Obstet. Gynecol. Neonatal Nurs."},{"key":"10.1016\/j.biopha.2024.116155_bib17","unstructured":"US CFF Patient Registry Report (2020)."},{"key":"10.1016\/j.biopha.2024.116155_bib18","article-title":"In utero mapping and development role of CFTR in lung and gastrointestinal tract of cystic fibrosis patients","author":"Li D","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.biopha.2024.116155_bib19","article-title":"Cystic fibrosis transmembrane conductance regulator modulators during pregnancy: a case series","volume":"13","author":"Kendle","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.biopha.2024.116155_bib20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.biopha.2024.116155_bib21","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.biopha.2024.116155_bib22","doi-asserted-by":"crossref","DOI":"10.1159\/000530261","article-title":"Prenatal cystic fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of cystic fibrosis","author":"Gomez-Montes","year":"2023","journal-title":"Fetal Diagn. Ther."},{"key":"10.1016\/j.biopha.2024.116155_bib23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.biopha.2024.116155_bib24","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.biopha.2024.116155_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcf.2015.11.013","article-title":"A successful uncomplicated CF pregnancy while remaining on Ivacaftor","volume":"15","author":"Kaminski","year":"2016","journal-title":"J. Cyst. Fibros.: Off. J. Eur. Cyst. Fibros. Soc."},{"key":"10.1016\/j.biopha.2024.116155_bib26","article-title":"To be or not to be on CFTR modulators during pregnancy: risks to be considered","author":"Vekaria","year":"2019","journal-title":"J. Cyst. Fibros.: Off. J. Eur. Cyst. Fibros. Soc."},{"key":"10.1016\/j.biopha.2024.116155_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey","author":"Nash","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.biopha.2024.116155_bib28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: a two center case series","volume":"20","author":"O'Connor","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.biopha.2024.116155_bib29","unstructured":"Patient Registry Annual Data Report, Cystic Fibrosis Australia."},{"key":"10.1016\/j.biopha.2024.116155_bib30","doi-asserted-by":"crossref","DOI":"10.1098\/rsfs.2019.0031","article-title":"Drug transport across the human placenta: review of placenta-on-a-chip and previous approaches","volume":"9","author":"Pemathilaka","year":"2019","journal-title":"Interface Focus"},{"key":"10.1016\/j.biopha.2024.116155_bib31","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/cpt1973144part2643","article-title":"Maternal and fetal distribution of drugs in pregnancy","volume":"14","author":"Mirkin","year":"1973","journal-title":"Clin. Pharm. Ther."},{"issue":"Pt 1","key":"10.1016\/j.biopha.2024.116155_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mod.2015.07.007","article-title":"Formation and maintenance of the BBB","volume":"138","author":"Blanchette","year":"2015","journal-title":"Mech. Dev."},{"key":"10.1016\/j.biopha.2024.116155_bib33","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1021\/acsptsci.0c00098","article-title":"The balance between the safety of mother, fetus, and newborn undergoing cystic fibrosis transmembrane conductance regulator treatments during pregnancy","volume":"3","author":"Qiu","year":"2020","journal-title":"ACS Pharm. Transl. Sci."},{"key":"10.1016\/j.biopha.2024.116155_bib34","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"4","author":"Percie du Sert","year":"2020","journal-title":"BMJ Open Sci."},{"key":"10.1016\/j.biopha.2024.116155_bib35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jcf.2021.06.005","article-title":"Entry of cystic fibrosis transmembrane conductance potentiator ivacaftor into the developing brain and lung","volume":"20","author":"Qiu","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.biopha.2024.116155_bib36","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acsptsci.0c00103","article-title":"Multiple reaction monitoring mass spectrometry for the drug monitoring of ivacaftor, tezacaftor, and elexacaftor treatment response in cystic fibrosis: a high-throughput method","volume":"3","author":"Reyes-Ortega","year":"2020","journal-title":"ACS Pharm. Transl. Sci."},{"key":"10.1016\/j.biopha.2024.116155_bib37","doi-asserted-by":"crossref","DOI":"10.3791\/56084","article-title":"Optimized LC-MS\/MS method for the high-throughput analysis of clinical samples of ivacaftor, its major metabolites, and lumacaftor in biological fluids of cystic fibrosis patients","author":"Schneider","year":"2017","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2024.116155_bib38","doi-asserted-by":"crossref","unstructured":"Lautt, W.W. Hepatic Circulation: Physiology and Pathophysiology (San Rafael (CA): Morgan & Claypool Life Sciences: 2009).","DOI":"10.4199\/C00004ED1V01Y200910ISP001"},{"key":"10.1016\/j.biopha.2024.116155_bib39","unstructured":"Marty, M., Kerndt, C.C. & Lui, F. Embryology, Fetal Circulation (Treasure Island (FL), 2023)."},{"key":"10.1016\/j.biopha.2024.116155_bib40","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s41598-023-28434-1","article-title":"Developmental changes in the extent of drug binding to rat plasma proteins","volume":"13","author":"Qiu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116155_bib41","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1021\/jm00180a022","article-title":"Relationship of octanol\/water partition coefficient and molecular weight to rat brain capillary permeability","volume":"23","author":"Levin","year":"1980","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2024.116155_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1007001923498","article-title":"Determinants of passive drug entry into the central nervous system","volume":"20","author":"Habgood","year":"2000","journal-title":"Cell Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2024.116155_bib43","unstructured":"European Medicines Agency. (2020). Assessment report Kaftrio (Trikafta) (2020)."},{"key":"10.1016\/j.biopha.2024.116155_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.577263","article-title":"Insights into patient variability during ivacaftor-lumacaftor therapy in cystic fibrosis","volume":"12","author":"Hanafin","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2024.116155_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1098-2302(199703)30:2<141::AID-DEV5>3.0.CO;2-Q","article-title":"Multiparous species present problems (and possibilities) to developmentalists","volume":"30","author":"Zorrilla","year":"1997","journal-title":"Dev. Psychobiol."},{"key":"10.1016\/j.biopha.2024.116155_bib46","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1146\/annurev-pharmtox-010818-021430","article-title":"Recent developments in understanding barrier mechanisms in the developing brain: drugs and drug transporters in pregnancy, susceptibility or protection in the fetal brain?","volume":"59","author":"Saunders","year":"2019","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"10.1016\/j.biopha.2024.116155_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fnins.2015.00021","article-title":"Efflux transporters in blood-brain interfaces of the developing brain","volume":"9","author":"Strazielle","year":"2015","journal-title":"Front Neurosci."},{"key":"10.1016\/j.biopha.2024.116155_bib48","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.3390\/ijms21093133","article-title":"What role does CFTR play in development, differentiation, regeneration and cancer?","volume":"21","author":"Amaral","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116155_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.742891","article-title":"A developmental role of the cystic fibrosis transmembrane conductance regulator in cystic fibrosis lung disease pathogenesis","volume":"9","author":"Huang","year":"2021","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2024.116155_bib50","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1369\/0022155414546190","article-title":"Cystic fibrosis transmembrane conductance regulator protein (CFTR) expression in the developing human brain: comparative immunohistochemical study between patients with normal and mutated CFTR","volume":"62","author":"Marcorelles","year":"2014","journal-title":"J. Histochem Cytochem"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224000362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224000362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:52:16Z","timestamp":1792097536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224000362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":50,"alternative-id":["S0753332224000362"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116155","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fetal drug exposure after maternally administered CFTR modulators Elexacaftor\/Tezacaftor\/Ivacaftor in a rat model","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116155"}}